Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine
1990
Enhancing Chemotherapy with Hydralazine
publication
Evidence: high
Author Information
Author(s): D.W. Siemann
Primary Institution: University of Rochester Cancer Center
Hypothesis
Can increasing hypoxia in tumor tissue with hydralazine enhance the chemosensitizing ability of nitroimidazoles?
Conclusion
The addition of hydralazine to chemotherapy protocols significantly enhances tumor cell kill without increasing bone marrow toxicity.
Supporting Evidence
- Hydralazine increased tumor cell kill by factors of 1.9 and 1.3 when combined with melphalan and misonidazole, respectively.
- The combination of hydralazine with chemotherapy did not increase bone marrow toxicity.
- Hydralazine administration after chemotherapy led to a therapeutic advantage.
Takeaway
This study found that a drug called hydralazine can help make cancer treatments more effective by increasing the amount of hypoxia in tumors, which helps other drugs work better.
Methodology
The study used KHT sarcoma and RIF-1 tumor models in mice to evaluate the effects of hydralazine on chemotherapy efficacy.
Participant Demographics
8-14 week-old female C3H/HeJ mice
Want to read the original?
Access the complete publication on the publisher's website